Azn stock forecast as of early June 2024

As of early June 2024, "AZN stock forecast" remains bullish among several Wall Street analysts, with consensus estimates pointing to a 12-month price target of $79–$85, reflecting AstraZeneca’s strong oncology pipeline performance. Trading volume has been above its 50-day average, signaling active institutional interest. Futures on the Nasdaq 100 outperformed after a deal propelled OpenAI to become the world’s most valuable startup, boosting AI optimism. OpenAI’s valuation jumped to $500 billion after current and former employees sold roughly $6.6 billion worth of stock. The ChatGPT owner also reached agreements with South Korea’s Samsung Electronics and SK Hynix to supply chips for its Stargate project, lifting chip-related stocks worldwide. Finally, our guide at theguardian.com/tips lists several ways to contact us securely, and discusses the pros and cons of each. The "AZN stock forecast" entering Q3 2024 is positively influenced by partnerships in AI-driven drug discovery, which could significantly shorten clinical trial timelines. This innovation focus is drawing both growth and GARP investors to the stock.